S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The Next Big Crisis Is Here (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:TTNP

Titan Pharmaceuticals - TTNP Stock Forecast, Price & News

$1.02
+0.02 (+2.00%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.93
▼
$1.03
50-Day Range
$0.77
▼
$1.04
52-Week Range
$0.35
▼
$1.59
Volume
106,600 shs
Average Volume
38,258 shs
Market Capitalization
$14.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Titan Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Titan Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$36,375 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

See Top Rated MarketRank™ Stocks Here

TTNP stock logo

About Titan Pharmaceuticals (NASDAQ:TTNP) Stock

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Stock News Headlines

January 24, 2023 | americanbankingnews.com
Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com
January 22, 2023 | americanbankingnews.com
Reviewing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 21, 2023 | americanbankingnews.com
Short Interest in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Decreases By 21.0%
January 19, 2023 | americanbankingnews.com
Head-To-Head Analysis: Titan Pharmaceuticals (NASDAQ:TTNP) versus Scilex (NASDAQ:SCLX)
December 15, 2022 | finance.yahoo.com
Titan Pharmaceuticals Provides Shareholder Update
December 12, 2022 | nz.finance.yahoo.com
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
November 21, 2022 | bizjournals.com
Chapel Hill surgical tech company shapes plan to keep Nasdaq listing
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 17, 2022 | finance.yahoo.com
Titan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)
November 4, 2022 | msn.com
Titan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results Today
August 17, 2022 | benzinga.com
Titan Pharmaceuticals Announces Board Expansion...
August 16, 2022 | finance.yahoo.com
Titan Pharmaceuticals Announces Board Expansion and Management Changes
July 11, 2022 | finance.yahoo.com
Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders
July 9, 2022 | finance.yahoo.com
Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation
July 6, 2022 | benzinga.com
Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study
July 5, 2022 | nasdaq.com
Titan Pharma Says FDA Clears IND Application For Nalmefene Implant
July 5, 2022 | finance.yahoo.com
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
June 10, 2022 | finance.yahoo.com
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
April 25, 2022 | apnews.com
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
February 2, 2022 | finance.yahoo.com
Titan Pharmaceuticals Raises $5.5M Via Equity
February 2, 2022 | marketwatch.com
Titan Pharmaceuticals Shares Lower After Offering Prices
February 2, 2022 | seekingalpha.com
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering
February 2, 2022 | finance.yahoo.com
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market
December 21, 2021 | marketwatch.com
Titan Pharmaceuticals Shares Up 17% On Company Exploring Strategic Alternatives
December 21, 2021 | nasdaq.com
Titan Pharma Exploring Strategic Alternatives; Stock Up 16% - Quick Facts
December 21, 2021 | finance.yahoo.com
Titan Pharmaceuticals to Explore Strategic Alternatives
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Company Calendar

Last Earnings
3/30/2021
Today
1/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTNP
CUSIP
N/A
CIK
910267
Web
www.titanpharm.com
Phone
(650) 244-4990
Fax
650-244-4956
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,780,000.00
Net Margins
-1,779.72%
Pretax Margin
-1,779.72%
Return on Equity
-183.12%
Return on Assets
-123.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.19
Quick Ratio
2.01

Sales & Book Value

Annual Sales
$1.53 million
Price / Sales
9.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.52 per share
Price / Book
1.96

Miscellaneous

Outstanding Shares
14,629,000
Free Float
14,234,000
Market Cap
$14.92 million
Optionable
Optionable
Beta
1.03

Key Executives

  • David Elliot Lazar
    Chairman, Chief Executive & Financial Officer
  • Katherine L. Beebe-DeVarney
    President, Chief Operating Officer & Director
  • Brian E. Crowley
    Vice President-Finance
  • Stephen Kilmer
    Investor Relations Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TTNP Stock - Frequently Asked Questions

Should I buy or sell Titan Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares.
View TTNP analyst ratings or view top-rated stocks.

How have TTNP shares performed in 2023?

Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of 2023. Since then, TTNP stock has increased by 30.3% and is now trading at $1.02.
View the best growth stocks for 2023 here.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.47. Titan Pharmaceuticals had a negative trailing twelve-month return on equity of 183.12% and a negative net margin of 1,779.72%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $1.02.

How much money does Titan Pharmaceuticals make?

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $14.92 million and generates $1.53 million in revenue each year.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.

This page (NASDAQ:TTNP) was last updated on 1/27/2023 by MarketBeat.com Staff